Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: A double-blind, fixed-dosage, controlled trial

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 152-156

  Spivak, Baruch ^a,c   Strous, Rael D ^b,c   Shaked, Ginette ^a   Shabash, Evgeny ^a   Kotler, Moshe ^a,b,c   Weizman, Abraham ^b,c,d  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; DRUG TOLERABILITY; EJACULATION DISORDER; EMOTIONAL DISORDER; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPOSALIVATION; LIBIDO DISORDER; MALE; MENTAL HEALTH; NAUSEA; NEUROTRANSMISSION; OUTPATIENT; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR AFFINITY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TRAFFIC ACCIDENT; VOMITING; WEIGHT REDUCTION;

ACCIDENTS, TRAFFIC; ADULT; AMBULATORY CARE FACILITIES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMANS; ISRAEL; MALE; MORPHOLINES; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 33646683309     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203195.65710.f0     Document Type: Article

References (37)

1. Richter ED. Death and injury from motor vehicle crashes in Israel: epidemiology, prevention and control. Int J Epidemiol. 1991;10:145-153.
2. Butler DJ, Moffic HS, Turkal NW. Post-traumatic stress reactions following motor vehicle accidents. Am Fam Physician. 1999;60:524-531.
3. Aharonson-Daniel L, Avitzour M, Barell V. Road traffic accidents, circumstances, diagnoses and severity of injury - data from the Israeli National Trauma Registry. Harefuah. 2001;140:919-922.
4. Blaszczynski A, Gordon K, Silove D, et al. Psychiatric morbidity following motor vehicle accidents: a review of methodological issues. Compr Psychiatry. 1998;39:111-121.
5. Mayou R, Bryand B, Duthie R. Psychiatric consequences of road traffic accidents. BMJ. 1993;307:647-651.
6. Fairbank J, Schlenger W, Saigh P, et al. An epidemiological profile of post-traumatic stress disorder - prevalence, comorbidity and risk factors. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia: Lippincott-Raven Publishers; 1995.
7. Kuch K, Cox BJ, Evans RJ. Posttraumatic stress disorder and motor vehicle accidents: a multidisciplinary overview. Can J Psychiatry. 1996;41:429-434.
8. Green MM, McFarlane AC, Hunter CE, et al. Undiagnosed posttraumatic stress disorder following motor vehicle accidents. Med J Aust. 1993;159:529-534.
9. Ursano RJ, Fullerton CS, Epstein RS, et al. Acute and chronic posttraumatic stress disorder in motor vehicle accident victims. Am J Psychiatry. 1999;156:589-595.
10. Mayou R, Tyndel S, Bryant B. Long-term outcome of motor vehicle accident injury. Psychosom Med. 1997;59:578-584.
11. Koren D, Arnon I, Klein E. Acute stress response and posttraumatic stress disorder in traffic accident victims: a one-year prospective, follow-up study. Am J Psychiatry. 1999;156:367-373.
12. Southwick SM, Krystal JH, Morgan CA, et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 1993;50:266-274.
13. Bremner JD, Krystal JH, Southwick SM, et al. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse. 1996;23:39-51.
14. Yehuda R, Southwick S, Giller EL, et al. Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis. 1992;180:321-325.
15. Geracioti TD Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001;158:1227-1230.
16. Birnbaum S, Gobeske KT, Auerbach J, et al. A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry. 1999;46:1266-1274.
17. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179:366-370.
18. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990;47:259-266.
19. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. Clin Psychiatry. 1994;55:517-522.
20. Connor KM, Sutherland SM, Tupler LA, et al. Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999;175:17-22.
21. Sutherland SM, Davidson JR. Pharmacotherapy for post-traumatic stress disorder. Psychiatr Clin North Am. 1994;17:409-423.
22. Hajos M, Fleishaker JC, Filipiak-Reisner JK, et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev. 2004;0:23-44.
23. Spivak B, Vered Y, Graff E, et al. Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. Biol Psychiatry. 1999;45:840-845.
24. Southwick SM, Bremner JD, Rasmusson A, et al. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;46:1192-1204.
25. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry. 2002;63:31-37.
26. Marmar CR, Schoenfeld F, Weiss DS, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1996;57(Suppl 8):66-70.
27. Davidson JR, Weisler RH, Malik M, et al. Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol. 1998;18:93-95.
28. Escalona R, Canive JM, Calais LA, et al. Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 2002;15:29-33.
29. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for Axis I DSM-IV Disorders, Patient Version (SCID-I/P), Version 2. New York: New York State Psychiatric Institute, Biometrics Research; 1995.
30. Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001;13:132-156.
31. Schwartz AC, Rothbaum BO. Review of sertraline in post-traumatic stress disorder. Expert Opin Pharmacother. 2002;3:1489-1499.
32. Connor KM, Davidson JR. Further psychometric assessment of the TOP-8: a brief interview-based measure of PTSD. Depress Anxiety. 1999;9:135-137.
33. Hamilton M. Rating scale for depression. J Neurol Neurosurg Psych. 1960;23:56
34. Hamilton M. The assessment of anxiety by rating. Br J Med Psychol. 1959;32:50-55.
35. Nutt DJ. The psychobiology of posttraumatic stress disorder. J Clin Psychiatry. 2000;61(Suppl 5):24-29.
36. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:85-102.
37. Tucker P, Zaninelli R, Yehuda R. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:860-868.